United States v. Glaxo Group Ltd.

1973-01-22

Headline: Government can challenge drug companies’ patents tied to anticompetitive licensing; Court allows patent invalidity claims and directs courts to consider compulsory sales and licensing to open the bulk drug market.

Holding: The Court held that the United States may challenge patents connected to illegal restraints of trade even when defendants do not invoke those patents, and that district courts may order compulsory sales and reasonable-royalty licensing as needed for effective relief.

Real World Impact:

Allows Government to seek invalidation of patents tied to anticompetitive licensing.
Can force patent owners to sell bulk drug on nondiscriminatory terms.
May require reasonable-royalty licenses to open competition among wholesalers and makers.

Topics: antitrust, patent validity, drug competition, compulsory licensing

Summary

Background

The dispute involved two British drug companies, ICI and Glaxo, that made and licensed griseofulvin, an antibiotic used in capsule or tablet form. ICI owned a U.S. patent on the dosage form and Glaxo owned patents on bulk manufacturing and a later “microsize” dosage form. In 1960 the companies pooled patents and imposed written covenants forbidding bulk sales or resales without consent; sublicenses to U.S. firms contained the same limits. The United States sued under the antitrust laws in 1968, alleging that those bulk-sale restraints were unreasonable per se; the trial court found per se violations but struck the Government’s patent-invalidity allegations and denied requests for mandatory bulk sales and compulsory patent licensing.

Reasoning

The key question was whether the Government may litigate patent validity in an antitrust suit even when defendants do not rely on the patents as a defense. The Court held that it may when the patents are tied to unlawful restraints and when the Government’s claims for relief are substantial. Relying on prior decisions recognizing that patents used to suppress competition can be challenged, the Court ruled the District Court erred in striking the patent claims and refusing relief and directed the lower court to consider patent validity and whether to order nondiscriminatory bulk sales and reasonable-royalty licensing.

Real world impact

The decision lets the Government seek to break patent-based barriers that help enforce anticompetitive licensing, potentially forcing patent owners to sell bulk drug and grant licenses on fair terms. The ruling is not a final finding on patent validity; the lower court must now adjudicate those patent questions and shape remedies.

Dissents or concurrances

A dissent warned this step broadens Government power without clear statutory authority and said the record did not prove the patents caused the illegal restraints.